10,090 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Acquired by Stephens Inc. AR

Stephens Inc. AR bought a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,090 shares of the company’s stock, valued at approximately $26,000.

A number of other institutional investors also recently modified their holdings of IBRX. SG Americas Securities LLC acquired a new stake in shares of ImmunityBio in the 3rd quarter valued at $222,000. Exchange Traded Concepts LLC lifted its stake in shares of ImmunityBio by 8.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company’s stock valued at $178,000 after purchasing an additional 3,722 shares during the last quarter. Wealth Effects LLC lifted its stake in shares of ImmunityBio by 3.4% in the 3rd quarter. Wealth Effects LLC now owns 90,500 shares of the company’s stock valued at $337,000 after purchasing an additional 3,000 shares during the last quarter. Courier Capital LLC raised its holdings in ImmunityBio by 50.0% in the 3rd quarter. Courier Capital LLC now owns 30,000 shares of the company’s stock worth $112,000 after acquiring an additional 10,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after acquiring an additional 4,545 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Price Performance

IBRX opened at $3.62 on Tuesday. The company has a market cap of $2.52 billion, a price-to-earnings ratio of -3.93 and a beta of 0.94. The firm has a 50 day simple moving average of $2.98 and a 200 day simple moving average of $3.80. ImmunityBio, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.53.

Analyst Upgrades and Downgrades

Several research analysts recently commented on IBRX shares. BTIG Research started coverage on shares of ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price on the stock. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. Finally, D. Boral Capital reiterated a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a research report on Friday.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.